← Leaderboards
Kevin G Pinney
Baylor University
$2,696,698
Attributed
$5,853,804
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $982.1K · FY2010–24$1M$750K$500K$250K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$5,853,804 · 4
By mechanism
R01$5,681,505 · 3
R15$172,299 · 1
Top collaborators
- Mary Lynn Trawick9 shared
- Rolf A Brekken4 shared
- Ralph P Mason4 shared
- Li Liu1 shared
Others in their field
Top investigators on “Prodrugs”
- Constance Ann Benson · University Of California, San Diego$84,289,569
- Susan Abushakra · Alzheon, Inc.$47,690,244
- Robert Turner Schooley · University Of Colorado Denver$47,231,917
- Lynn Kirkpatrick · Ensysce Biosciences, Inc.$26,039,397
- David Heimbrook · Leidos Biomedical Research, Inc.$21,781,988
- Kevin V Grimes · Stanford University$14,783,804
Research focus
ProdrugsGrowthAntibodiesTreatment EfficacyInnovationBlood VesselsNecrosisTumorTumor GrowthDesignCellsIn VivoBaseBioluminescence ImagingLeadChemotherapyLight EmissionAcuteClinicLuciferasesInvestigationCancer TherapyDoseClinical Trials
Grant awards (15)
Vascular image-guided optimization of response (VIGOR) to therapy in kidney cancer$462,812
R01 · FY2024 · CA
Vascular image-guided optimization of response (VIGOR) to therapy in kidney cancer$480,760
R01 · FY2023 · CA
Novel Protein Engineered Drug Conjugates Targeting Phosphatidylserine for the Treatment of Breast Cancer$466,250
R01 · FY2023 · CA · contact PI
Vascular image-guided optimization of response (VIGOR) to therapy in kidney cancer$466,346
R01 · FY2022 · CA
Novel Protein Engineered Drug Conjugates Targeting Phosphatidylserine for the Treatment of Breast Cancer$466,250
R01 · FY2022 · CA · contact PI
Novel Protein Engineered Drug Conjugates Targeting Phosphatidylserine for the Treatment of Breast Cancer$475,608
R01 · FY2021 · CA · contact PI
Vascular image-guided optimization of response (VIGOR) to therapy in kidney cancer$474,043
R01 · FY2021 · CA
Vascular image-guided optimization of response (VIGOR) to therapy in kidney cancer$492,054
R01 · FY2020 · CA
Novel Protein Engineered Drug Conjugates Targeting Phosphatidylserine for the Treatment of Breast Cancer$490,013
R01 · FY2020 · CA · contact PI
Chemotherapeutic Agents with Enhanced Selectivity for the Tumor Microenvironment$274,502
R01 · FY2014 · CA · contact PI
Chemotherapeutic Agents with Enhanced Selectivity for the Tumor Microenvironment$266,013
R01 · FY2013 · CA · contact PI
Chemotherapeutic Agents with Enhanced Selectivity for the Tumor Microenvironment$282,992
R01 · FY2012 · CA · contact PI
Chemotherapeutic Agents with Enhanced Selectivity for the Tumor Microenvironment$282,992
R01 · FY2011 · CA · contact PI
Chemotherapeutic Agents with Enhanced Selectivity for the Tumor Microenvironment$300,870
R01 · FY2010 · CA · contact PI
Novel Serotonin Reuptake Inhibitors for Autism Treatment$172,299
R15 · FY2004 · ES